Transaction DateRecipientSharesTypePriceValue
16th February 2021Joseph P Hagan4,144Open or private sale$1.72$7,127.68
14th August 2020Joseph P Hagan4,245Open or private sale$0.60$2,567.80
25th June 2020Joseph P Hagan7,500Grant/award etc.$0.00
25th June 2020John Peter Walker7,500Grant/award etc.$0.00
25th June 2020Steven Lo146,250Grant/award etc.$0.00
25th June 2020Kenneth Greathouse7,500Grant/award etc.$0.00
25th June 2020Donald J Kellerman18,750Grant/award etc.$0.00
25th June 2020Hayley Lewis18,750Grant/award etc.$0.00
25th June 2020Kleanthis G Xanthopoulos7,500Grant/award etc.$0.00
25th June 2020Linda S Grais7,500Grant/award etc.$0.00
Zosano Pharma
Zosano Pharma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Zosano Pharma Corp. is a clinical stage pharmaceutical company. It engages in the provision of systemic administration of therapeutics to patients. The company was founded in January 2012 and is headquartered in Fremont, CA.

Ticker: ZSAN
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1587221
Employees: 56
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $11 M (0%)
Other Assets, Current: $8 Th (33%)
Assets, Current: $11 M (65%)
Property, Plant and Equipment, Net: $31 M (24%)
Other Assets, Noncurrent: $3 Th (0%)
Assets: $48 M (26%)
Accounts Payable, Current: $5 M (10%)
Liabilities, Current: $17 M (1%)
Other Liabilities, Noncurrent: $8 Th (-46%)
Liabilities: $29 M (3%)
Common Stock, Value, Issued: $6 Th (200%)
Common Stock, Shares, Issued: $57 M (143%)
Additional Paid in Capital, Common Stock: $334 M (8%)
Retained Earnings (Accumulated Deficit): $315 M (0%)
Stockholders' Equity (Parent): $18 M (0%)
Liabilities and Equity: $48 M (26%)
Research and Development: $5 M (-52%)
General and Administrative Expenses: $3 M (-52%)
Operating Income/Loss: $8 M (-52%)